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Abstract
Candida albicans is the leading fungal pathogen of humans, causing life-threatening disease in immunocompromised
individuals. Treatment of candidiasis is hampered by the limited number of antifungal drugs whose efficacy is compromised
by host toxicity, fungistatic activity, and the emergence of drug resistance. We previously established that the molecular
chaperone Hsp90, which regulates the form and function of diverse client proteins, potentiates resistance to the azoles in C.
albicans and in the model yeast Saccharomyces cerevisiae. Genetic studies in S. cerevisiae revealed that Hsp90’s role in azole
resistance is to enable crucial cellular responses to the membrane stress exerted by azoles via the client protein calcineurin.
Here, we demonstrate that Hsp90 governs cellular circuitry required for resistance to the only new class of antifungals to
reach the clinic in decades, the echinocandins, which inhibit biosynthesis of a critical component of the fungal cell wall.
Pharmacological or genetic impairment of Hsp90 function reduced tolerance of C. albicans laboratory strains and resistance
of clinical isolates to the echinocandins and created a fungicidal combination. Compromising calcineurin function
phenocopied compromising Hsp90 function. We established that calcineurin is an Hsp90 client protein in C. albicans:
reciprocal co-immunoprecipitation validated physical interaction; Hsp90 inhibition blocked calcineurin activation; and
calcineurin levels were depleted upon genetic reduction of Hsp90. The downstream effector of calcineurin, Crz1, played a
partial role in mediating calcineurin-dependent stress responses activated by echinocandins. Hsp90’s role in echinocandin
resistance has therapeutic potential given that genetic compromise of C. albicans HSP90 expression enhanced the efficacy
of an echinocandin in a murine model of disseminated candidiasis. Our results identify the first Hsp90 client protein in C.
albicans, establish an entirely new role for Hsp90 in mediating resistance to echinocandins, and demonstrate that targeting
Hsp90 provides a promising therapeutic strategy for the treatment of life-threatening fungal disease.
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Introduction
Candida species have intimate yet perilous connections with their
human hosts. They are commensals of the human microbiota of the
gastrointestinal tract, mucous membranes, and skin. They also rank
as the most common causative agents of invasive fungal infections
and are responsible for a broad spectrum of disease [1,2]. For the
immunocompetent individual, Candida infections are most often
superficial in nature including thrush and vaginitis. For the
immunocompromised individual, these opportunists are far more
menacing,astheycandisseminateandcauselife-threateningsystemic
disease. Candida albicans is the most frequently encountered Candida
species in the clinic and is the fourth most common cause of hospital
acquired infectious disease with mortality rates approaching 50%
[2,3]. The frequency of fungal infections continues to increase in pace
withthegrowingimmunocompromised patientpopulation,including
individualsundergoing chemotherapy, transplantation of solid organs
or hematopoietic stem cells, as well as those infected with HIV [4,5].
Treatment of invasive fungal infections remains notoriously
challenging, due in large part to the limited availability of clinically
useful antifungal drugs. Fungi are eukaryotes and share close
evolutionary relationships with their human hosts [6,7]. This
makes the identification of drug targets in fungi that do not have
homologs of similar function and susceptibility to inhibition in
humans a daunting task. Most antifungal drugs in clinical use
target the biosynthesis or function of ergosterol, the predominant
sterol of fungal membranes, or the biosynthesis of (1,3)-b-D-
glucan, a critical component of the fungal cell wall [8,9]. The
azoles are the largest class of antifungal drugs in clinical use and
have been deployed for several decades. They inhibit lanosterol
14a-demethylase, blocking ergosterol biosynthesis and resulting in
the accumulation of a toxic sterol intermediate that disrupts
membrane integrity and results in cell membrane stress. The
echinocandins are the only new class of antifungal drug to be
approved for clinical use in decades and inhibit (1,3)-b-D-glucan
synthase, disrupting cell wall integrity and resulting in cell wall
stress.
The efficacy of antifungal drugs can be hampered by fungistatic
rather than fungicidal activity, by host toxicity, and by the
emergence of drug resistance. The azoles are generally fungistatic
PLoS Pathogens | www.plospathogens.org 1 July 2009 | Volume 5 | Issue 7 | e1000532against Candida species and many immunocompromised patients
are on long-term treatment due to persistent infections or on
prophylaxis to prevent future infections. This creates favorable
conditions for the evolution of drug resistance. In experimental
populations and clinical isolates, resistance often emerges by
multiple mechanisms [8–10]. Resistance mechanisms that mini-
mize the impact of the drug include overexpression of multidrug
transporters or alterations of the target enzyme. Other mecha-
nisms function to minimize drug toxicity, such as loss of function of
Erg3 in the ergosterol biosynthesis pathway, which blocks the
production of a toxic sterol that would otherwise accumulate when
the azoles inhibit their target. Mechanisms that mitigate drug
toxicity are often dependent upon cellular stress responses that are
crucial for tolerance of the membrane stress exerted by azoles
[8,9]. Far less is known about resistance to echinocandins, at least
in part due to their more recent approval for clinical use. The most
common mechanism of echinocandin resistance is mutation of the
drug target [11]. The (1,3)-b-D-glucan synthase complex consists
of a regulatory subunit, Rho1, and a catalytic subunit encoded by
FKS1, FKS2, and FKS3. Resistance is most commonly associated
with characteristic mutations in FKS1 that reduce sensitivity of the
enzyme to inhibition by echinocandins [11–13]. While the
echinocandins are thought to be fungicidal against C. albicans, this
organism has the capacity for robust growth at high drug
concentrations, known as the paradoxical effect [14]. C. albicans
may utilize multiple cellular stress response pathways to tolerate
cell wall stress induced by echinocandins including upregulation of
other components of the cell wall as well as responses mediated by
the cell wall integrity signaling pathway [15,16].
A key regulator of cellular stress responses crucial for resistance
to the azoles is the molecular chaperone Hsp90. Hsp90 is an
essential chaperone that regulates the form and function of many
key signal transducers [17–19]. Pharmacological inhibition of
Hsp90 blocks the emergence of azole resistance in C. albicans and
abrogates resistance of laboratory mutants and clinical isolates that
evolved resistance in a human host [20,21]. Impairing Hsp90
function converts the fungistatic azoles into a fungicidal combi-
nation and enhances the therapeutic efficacy of azoles in two
metazoan models of disseminated C. albicans infection [22].
Hsp90’s role in the emergence and maintenance of azole
resistance is conserved in the model yeast Saccharomyces cerevisiae
[21]. The key mediator of Hsp90-dependent azole resistance is
calcineurin, a protein phosphatase that regulates crucial responses
to environmental stress, including the membrane stress exerted by
exposure to azoles [20,21]. In both S. cerevisiae and C. albicans,
compromising calcineurin phenocopies compromising Hsp90,
reducing azole resistance of diverse mutants. In S. cerevisiae,
Hsp90 interacts physically with the catalytic subunit of calcineurin
keeping it stable and poised for activation [23]. High-throughput
genomic and proteomic studies have mapped Hsp90 physical
interactors in S. cerevisiae [24], while to date not a single Hsp90
client protein has been identified in C. albicans.
Given Hsp90’s role in azole resistance, we postulated that this
chaperone might also govern crucial responses to the cell wall
stress exerted by echinocandins in C. albicans. We recently
discovered that Hsp90 is required for the basal tolerance of
Aspergillus species to echinocandins, which are fungistatic against
Aspergillus species, and that Hsp90 inhibitors enhance the efficacy
of echinocandins in an invertebrate model of Aspergillus fumigatus
infection [21,22]. A. fumigatus is the principal causal agent of
invasive aspergillosis with alarming mortality rates up to 90% that
still remain at 40% with the best current treatment options
[25,26]. Compromising calcineurin tracks with compromising
Hsp90, enhancing the activity of echinocandins [27,28]. While
initial studies did not detect a role for Hsp90 in echinocandin
resistance in C. albicans [21], there are two lines of evidence
implicating the Hsp90 client protein calcineurin in mediating
responses to cell wall stress in this pathogen. First, stimulation of
chitin synthesis rescues C. albicans from echinocandins and this
stimulation is mediated via calcineurin in concert with the cell wall
integrity signaling pathway and the high osmolarity glycerol
signaling pathway [15,16]. Second, inhibition of calcineurin can
block the paradoxical growth of C. albicans observed at elevated
echinocandin concentrations [29]. Whether calcineurin mediates
basal tolerance to echinocandins is unclear given that in one study,
deletion of calcineurin enhanced the killing activity of an
echinocandin [30], while in another study there was no effect
[31]. Thus, if Hsp90 regulates calcineurin function, then it is
poised to mediate crucial cellular responses to the echinocandins.
Here, we investigated Hsp90’s role in tolerance to echinocan-
dins in C. albicans. We found that pharmacological or genetic
compromise of Hsp90 function reduced tolerance of laboratory
strains to the echinocandins and created a fungicidal combination.
Inhibition of Hsp90 also reduced resistance acquired by mutation
in FKS1 in both laboratory-derived mutants and clinical isolates
that acquired resistance in a human host. Compromising
calcineurin function phenocopied compromising Hsp90 function.
Consistent with calcineurin being the key mediator of Hsp90-
dependent echinocandin tolerance, we established that calcineurin
is an Hsp90 client protein in C. albicans. The downstream effector
of calcineurin, Crz1, played a partial role in mediating calcineurin-
dependent stress responses that are activated by echinocandins.
Hsp90’s key role in governing crucial responses to cell wall stress
exerted by echinocandins was not conserved in S. cerevisiae,
emphasizing the importance of performing molecular studies in
the pathogen. In a murine model of disseminated candidiasis,
genetic impairment of HSP90 expression enhanced the therapeutic
efficacy of an echinocandin. Our findings identify the first Hsp90
client protein in C. albicans and establish an entirely new role for
Hsp90 in mediating echinocandin resistance. Further, our results
demonstrate that targeting Hsp90 provides a promising therapeu-
tic strategy for the treatment of life-threatening disease.
Author Summary
Fungal pathogens pose a serious threat to people with
compromised immune systems. Chief among the oppor-
tunistic fungal pathogens is Candida albicans. Treatment of
C. albicans infections remains challenging because there
are very few effective drugs and the pathogen has evolved
many strategies to survive drug exposure. The echinocan-
dins are the only new class of antifungal drug to reach the
clinic in decades and they block biosynthesis of an
essential component of the fungal cell wall. We discovered
that the molecular chaperone Hsp90, which is required for
its client proteins in the cell to fold and function, governs
the ability of C. albicans to survive exposure to echino-
candins. Compromising Hsp90 function renders the
echinocandins more effective at killing C. albicans labora-
tory strains and clinical isolates. Hsp90 orchestrates the
crucial responses to cell wall stress exerted by the
echinocandins by enabling the function of its client
protein calcineurin, which allows the fungus to survive
otherwise lethal conditions. Our results suggest that
compromising Hsp90 function provides a powerful and
much-needed strategy to render existing antifungal drugs
more effective in the treatment of life-threatening fungal
infections.
Hsp90 Governs Echinocandin Resistance
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Hsp90 plays a crucial role in echinocandin tolerance of
Candida albicans
To determine the impact of compromising Hsp90 function on
tolerance to echinocandins, we first used two structurally unrelated
inhibitors geldanamycin (GdA) or radicicol (RAD) that bind with
high affinity to Hsp90’s unusual adenosine triphosphate (ATP)
binding pocket and inhibit ATP-dependent chaperone function
[32,33]. We used concentrations that abrogate resistance to azoles,
but have no impact on growth on their own [20–22]. The impact
of Hsp90 inhibitors on tolerance to the widely used echinocandin
micafungin (MF) was evaluated using an antifungal susceptibility
test that measures growth across a gradient of MF concentrations
relative to a MF-free growth control. Both strains tested showed
robust tolerance to MF (Figure 1A). Inhibition of Hsp90 with GdA
or RAD dramatically enhanced sensitivity to MF in either
synthetic defined medium (Figure 1A) or in rich medium (Figure
S1A). Comparable effects were observed with another widely used
echinocandin, caspofungin (CS, Figure S1B). The same trends
were observed when a dilution series of cells was spotted on solid
medium with a fixed concentration of MF; concentrations of
Hsp90 inhibitors that had no impact on growth on their own
enhanced susceptibility to MF (Figure 1B). Notably, while synergy
of Hsp90 inhibitors with MF was observed in both liquid and solid
media (Figure 1), the synergy with CS was restricted to liquid
medium (data not shown). This explains why the synergy between
Hsp90 inhibitors and echinocandins was not detected in a previous
study, which used CS on solid medium [21]. The basis for the
different responses with MF and CS on solid medium is unclear
and the response with a third echinocandin, anidulafungin,
remains to be determined. Strains were more sensitive to
echinocandins in a medium used for clinical susceptibility testing
(RPMI, Figure S1C and Figure S1D), however, compromising
Hsp90 or calcineurin function further enhanced the sensitivity
(Figure S1C).
Next, we exploited genetic regulation of Hsp90 to validate the
impact of compromising Hsp90 function on echinocandin
tolerance. Deletion of one HSP90 allele had negligible effect on
MF tolerance (Figure 1C and D). Replacing the native HSP90
promoter of the heterozygote with a tetracycline-repressible
promoter has no effect on basal Hsp90 levels in the absence of
tetracycline at 30uC, but blocks induction of HSP90 in response to
stress such as elevated temperature of 37uC or exposure to
antifungal drugs [22]. Even in the absence of tetracycline,
compromising HSP90 expression in the tetO-HSP90/hsp90D strain
resulted in hypersensitivity to MF in both liquid and solid media
(Figure 1C and 1D). While the tetO-HSP90/hsp90D strain also had
a reduced growth rate, Hsp90 inhibitors at concentrations that
have no effect on growth on their own dramatically enhanced
echinocandin sensitivity ruling out the possibility that the
hypersensitivity is simply due to reduced growth rate (Figure 1B).
Restoring a wild-type HSP90 allele to the tetO-HSP90/hsp90D
strain complemented both the reduced growth rate and the
hypersensitivity to MF. Thus, pharmacological and genetic studies
establish that Hsp90 enables tolerance to echinocandins.
Compromising calcineurin function phenocopies
compromising Hsp90 function
It is now well established that a key mediator of Hsp90-
dependent azole resistance is calcineurin, a protein phosphatase
that regulates numerous responses to membrane stress in C.
albicans [8,20,21]. If Hsp90 governs crucial cellular responses to
echinocandins via calcineurin, then inhibition of calcineurin
should phenocopy Hsp90 inhibition.
We initially compromised calcineurin function pharmacologi-
cally using two structurally unrelated inhibitors cyclosporin A
(CsA) and FK506 that inhibit calcineurin by distinct mechanisms
[34]. CsA binds to Cpr1, a peptidyl-prolyl cis-trans isomerase
(cyclophilin A), forming a drug-protein complex that blocks
calcineurin function. FK506 forms a different drug-protein
complex that binds to the structurally unrelated peptidyl-prolyl
cis-trans isomerase FKBP12 to block calcineurin function. We
used concentrations of CsA and FK506 that had no impact on
growth on their own but that abrogate azole resistance [20,21].
Inhibition of calcineurin with either CsA or FK506 abolished MF
tolerance of C. albicans (Figure 2).
Next, we abolished calcineurin function genetically by either
deleting the gene encoding the catalytic subunit of calcineurin,
CNA1, or by deleting the gene encoding the regulatory subunit of
calcineurin required for its activation, CNB1. In both cases, loss of
calcineurin function abrogated MF tolerance (Figure 2). Recon-
stituting a wild-type allele of CNB1 restored tolerance. Thus,
impairing calcineurin function recapitulates the effects of impair-
ing Hsp90, reducing echinocandin tolerance of C. albicans.
Inhibition of Hsp90 or calcineurin creates a fungicidal
combination with MF
The echinocandins are generally fungicidal against yeast species
such as C. albicans [11]. However, C. albicans is able to grow
vigorously at intermediate echinocandin concentrations in labo-
ratory growth conditions (Figures 1 and 2 and Figure S1). Our
previous assays did not resolve whether inhibition of Hsp90 or
calcineurin results in a complete block in fungal growth in the
presence of echinocandins or whether it creates a fungicidal
condition.
To determine if compromising Hsp90 or calcineurin function is
fungistatic or fungicidal in the presence of echinocandins, we used
tandem assays with an antifungal susceptibility test followed by
spotting onto rich medium without any inhibitors. The common
approach to address cidality by measuring colony forming units
(CFU) in a culture exposed to treatment over time worked well for
azoles [22], but was not accurate for echinocandins. Exposure of
C. albicans to MF caused severe clumping such that large
aggregates of cells were not separable, rendering CFU counts
inaccurate (data not shown). A strain with wild-type or
heterozygous HSP90 levels was able to grow on rich medium
following exposure to all concentrations of MF tested (Figure 3, left
panel). Genetic compromise of HSP90 expression in the tetO-
HSP90/hsp90D strain or pharmacological inhibition of Hsp90 with
GdA was cidal in combination with any dose of MF tested; no cells
were able to grow on the rich medium following exposure to the
treatments (Figure 3). Comparable effects were seen with genetic
or pharmacological compromise of calcineurin function (Figure 3).
Thus, Hsp90 and calcineurin regulate crucial cellular responses for
surviving the cell wall stress exerted by the echinocandins.
Calcineurin is an Hsp90 client protein in C. albicans
Compromising calcineurin pharmacologically or genetically
phenocopies compromising Hsp90 suggesting a functional rela-
tionship between these regulators. Genetic studies established that
calcineurin is a key mediator of Hsp90-dependent azole resistance
[20,21]. In S. cerevisiae, Hsp90 physically interacts with the catalytic
subunit of calcineurin keeping it stable and poised for activation
[23]. High-throughput studies have mapped Hsp90 physical
interactors in S. cerevisiae [24], while to date not a single Hsp90
client protein has been characterized in C. albicans.
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interact in C. albicans, we engineered strains harboring epitope-
tagged proteins for co-immunoprecipitation. We tagged the
catalytic subunit of calcineurin, Cna1, at the C-terminus using a
6X-histidine and FLAG epitope tag that has been used successfully
for purification of the C. albicans septin complex [35]. The Cna1-
Figure 1. Hsp90 plays a crucial role in echinocandin tolerance of Candida albicans. (A) Pharmacological inhibition of Hsp90 with GdA or RAD
reduces MF tolerance of C. albicans laboratory strains in an MIC assay. Assays were done in synthetic defined medium at 30uC for 72 hours. Optical
densities were averaged for duplicate measurements and normalized relative to MF-free controls (see colour bar). (B) Pharmacological inhibition of
Hsp90 reduces MF tolerance on solid rich medium (YPD). Cells were spotted in fivefold dilutions (from 1610
6 cells/ml) onto plates with a fixed
concentrationofMF(30 ng/ml),GdA,or RAD, asindicated,andwerephotographedafter48 hours inthedarkat30uC.(C)Geneticcompromise ofHsp90
expression reduces MF tolerance in an MIC assay. The assay was performed and analyzed as in part A. (D) Genetic compromise of Hsp90 expression
reduces MF tolerance on solid rich medium (YPD). The assay was performed and analyzed as in part B except plates were photographed after 72 hours.
doi:10.1371/journal.ppat.1000532.g001
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canonical calcineurin-dependent response to calcium stress (Figure
S2A). Immunoprecipitation with anti-FLAG agarose co-purified
both FLAG-tagged Cna1 and wild-type Hsp90 (Figure 4A). For
the control strain lacking the tagged CNA1 allele, Hsp90 was
present in the input but was not immunoprecipitated. To further
validate the physical interaction between Hsp90 and calcineurin,
we performed the reciprocal co-immunoprecipitation using the
same tagged allele of calcineurin in addition to an HSP90 allele
tagged at the C-terminus with a tandem affinity purification (TAP)
tag which consists of a calmodulin binding peptide, a TEV
cleavage site and two IgG binding domains of Staphylococcus aureus
protein A that has been used with great success in S. cerevisiae [36].
The Hsp90-TAP protein is functional and able to support growth
Figure 2. Compromising calcineurin function phenocopies compromising Hsp90 function. Deletion of either the catalytic subunit of
calcineurin, CNA1, or the regulatory subunit of calcineurin, CNB1, abrogates MF tolerance. Pharmacological inhibition of calcineurin with either CsA or
FK506 also abrogates MF tolerance. The assay was performed and analyzed as in Figure 1A.
doi:10.1371/journal.ppat.1000532.g002
Figure 3. Inhibition of Hsp90 or calcineurin creates a fungicidal combination with MF. An MIC assay with four-fold MF dilutions was
performed in YPD with or without either the Hsp90 inhibitor GdA or the calcineurin inhibitor CsA and incubated for 72 hours at 30uC. Cells from the
MIC assay were spotted onto solid YPD medium and incubated at 30uC for 48 hours.
doi:10.1371/journal.ppat.1000532.g003
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tation with IgG sepharose for the TAP tag, co-purifies both
Hsp90-TAP and Cna1-His-FLAG (Figure 4B). For the control
strain lacking Hsp90-TAP, the tagged allele of calcineurin was
present in the input but was not immunoprecipitated. Thus,
reciprocal co-immunoprecipitation demonstrates physical interac-
tion between Hsp90 and calcineurin in C. albicans.
If calcineurin is an Hsp90 client protein, then one would expect
that inhibition of Hsp90 function would compromise calcineurin
activation. To determine if this is indeed the case, we used a well-
established reporter system that exploits the calcineurin down-
stream effector Crz1. Crz1 is a transcription factor that is
dephosphorylated by calcineurin in response to calcineurin
activation by calcium [37–39]. Dephosphorylated Crz1 translo-
Figure 4. Calcineurin is an Hsp90 client protein in C. albicans. (A) Hsp90 and calcineurin physically interact as measured by co-
immunoprecipitation of Hsp90 with Cna1-HisFLAG. Immunoprecipitation of HisFLAG-tagged Cna1 with anti-FLAG M2 affinity agarose, co-purifies
Hsp90. Hsp90 was not immunoprecipitated by anti-FLAG M2 affinity agarose in control cells harboring untagged Cna1. (B) Hsp90 and calcineurin
physically interact as measured by the reciprocal co-immunoprecipitation of Cna1-HisFLAG with Hsp90-TAP. Immunoprecipitation of Hsp90-TAP with
IgG agarose, co-purifies Cna1-HisFLAG. Cna1-HisFLAG was not immunoprecipitated by IgG agarose in control cells harboring untagged Hsp90. (C)
Calcineurin activation is blocked by pharmacological inhibition of Hsp90. A strain harboring a UTR2p-lacZ construct was incubated in rich medium
with no treatment (U) or with 0.2 M CaCl2 (Ca) to activate calcineurin. The impact of the calcineurin inhibitor CsA (10 mM), or the Hsp90 inhibitors
GdA (5 mM) or RAD (5 mM) on calcineurin activation was determined by measurement of b-galactosidase activity. Data are means6standard
deviations for triplicate samples. (D) Genetic reduction of Hsp90 levels results in depletion of calcineurin. All strains shown in this panel have one
allele of Cna1-HisFLAG in addition to the indicated genotype. Even when fully induced in the maltose, expression of Hsp90 from the MAL2 promoter
is not as strong as from the native promoter, while glucose results in further reduction of Hsp90 expression. This reduction of Hsp90 levels is
accompanied by depletion of calcineurin. Top two panels, immune blot analysis of Hsp90 levels relative to the histone H3 loading control (5 mg
protein loaded per well). Bottom two panels, immune blot analysis of Cna1-HisFLAG relative to the histone H3 loading control (50 mg protein loaded
per well).
doi:10.1371/journal.ppat.1000532.g004
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calcineurin-dependent response elements (CDREs) in their
promoters. We used a strain harboring a construct with the
UTR2 promoter, which contains a CDRE element and is
regulated by calcineurin [37], fused to lacZ and integrated at the
UTR2 locus [40]. In S. cerevisiae, a similar reporter that contains
four tandem copies of CDRE and a CYC1 minimal promoter
driving lacZ has been used extensively [39]. As expected, exposure
of cells containing the UTR2-lacZ reporter to calcium chloride
resulted in activation of calcineurin relative to the untreated
control (P,0.001, ANOVA, Bonferroni’s Multiple Comparison
Test Figure 4C). Inhibition of calcineurin with CsA caused a
dramatic reduction of calcineurin activation (P,0.001). Inhibition
of Hsp90 with GdA or RAD was as effective in blocking
calcineurin activation as CsA (Figure 4C).
A hallmark of Hsp90 client proteins is that they are destabilized
and degraded upon compromising Hsp90 function. To determine
if calcineurin levels are reduced upon genetic reduction of Hsp90,
we turned to a strain with its only HSP90 allele regulated by the
MAL2 repressible promoter. In this system, HSP90 expression is
induced by maltose and repressed by glucose (Figure 4D). The
MAL2 promoter does not drive as strong expression as the native
HSP90 promoter, thus even when fully induced in maltose, the
MAL2p-HSP90/hsp90D strain had a modest reduction of Hsp90
levels relative to a heterozygote with its only HSP90 allele under
the control of the native promoter (Figure 4D). Growth of cells in
an equal mixture of glucose and maltose as the carbon source
resulted in a dramatic reduction of Hsp90 levels (Figure 4D).
Under these conditions, the MAL2p-HSP90/hsp90D strain has
reduced growth rate and reaches approximately half the stationary
phase cell density as a wild-type strain [40]. This genetic depletion
of Hsp90 was accompanied by a dramatic reduction of calcineurin
levels as measured by immunoblot hybridization with an anti-
FLAG antibody to detect the Cna1-His-FLAG protein (Figure 4D).
Hybridization with an anti-H3 antibody confirmed comparable
amounts of protein were loaded for all strains. Taken together,
these results support the model that calcineurin is a client protein
in C. albicans.
Azoles and echinocandins activate calcineurin-
dependent stress responses
Due to the important role of calcineurin in mediating crucial
responses to the stress exerted by exposure to azoles and
echinocandins [20,21,30,31], we postulated that these drugs would
cause activation of calcineurin. We used the UTR2p-lacZ reporter
to monitor calcineurin activation in response to concentrations of
the azole antifungal drug fluconazole (FL) and the echinocandin
MF that each cause modest inhibition of growth. Preliminary
studies revealed maximum activation of calcineurin occurred at
different time points in response to the different drugs (data not
shown). Exposure to MF for 8 hours caused significant activation
of calcineurin (Figure 5A, P,0.001, ANOVA, Bonferroni’s
Multiple Comparison Test). Pharmacological inhibition of calci-
neurin or Hsp90 blocked MF-induced calcineurin activation
(P,0.001). Treatment conditions were optimized such that all
cultures underwent comparable growth with equivalent protein
yields. Exposure to FL for 24 hours also led to significant
calcineurin activation (Figure 5B, P,0.001, ANOVA, Bonferro-
ni’s Multiple Comparison Test). Inhibition of calcineurin or Hsp90
blocked FL-induced calcineurin activation (Figure 5B, P,0.001).
Thus, both echinocandins and azoles activate calcineurin-
dependent stress responses mediated via the transcription factor
Crz1 and inhibition of Hsp90 blocks these responses.
The calcineurin-dependent transcription factor Crz1 plays
a partial role in echinocandin tolerance
Crz1is the key mediator of calcineurin-dependent transcriptional
responses [37,41] and is implicated in tolerance to azoles in both S.
cerevisiae and C. albicans [20,42]. While deletion of calcineurin causes
a complete loss of azole tolerance, deletion of CRZ1 causes only a
partial reduction in both species. To determine if Crz1 is also an
important effector of calcineurin-dependent echinocandin toler-
ance, we compared the phenotypic consequences of deletion of
CRZ1 with deletion of the catalytic subunit of calcineurin, CNA1.
Mutants with homozygous deletion of CNA1 were hypersensitive to
MF in both liquid and solid assays (Figures 2 and 6). Two
independent crz1 null mutants demonstrated partial loss of MF
tolerance, but were not as sensitive as the cna1 mutants (Figure 6).
Reconstitution of a wild-type CRZ1 allele restored MF tolerance.
Figure 5. Echinocandins and azoles activate calcineurin-
dependent stress responses. (A) The echinocandin MF activates
calcineurin. A strain harboring a UTR2p-lacZ construct was incubated in
rich medium without treatment (U) or with 30 ng/ml MF in combination
with the calcineurin inhibitor CsA (10 mM) or the Hsp90 inhibitor RAD
(5 mM),asindicated,for8 hours.Dataaremeans6standarddeviationsfor
triplicate samples. (B) The azole fluconazole (FL) activates calcineurin in
an Hsp90-dependent manner. A strain harboring a UTR2p-lacZ construct
was incubatedin rich mediumwithout treatment (U) or with 16 mg/ml FL
in combination with the calcineurin inhibitor CsA (10 mM) or the Hsp90
inhibitor RAD (5 mM), as indicated, for 24 hours.
doi:10.1371/journal.ppat.1000532.g005
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din tolerance, but other calcineurin downstream effectors affecting
this trait remain to be identified.
Clinical relevance of Hsp90 and calcineurin-mediated
echinocandin resistance
To determine if Hsp90 and calcineurin are involved in bona fide
echinocandin resistance arising due to mutations in the target Fks1
we tested for synergy between inhibitors of Hsp90 (GdA) or
calcineurin (CsA) and the echinocandin MF. We utilized a
checkerboard format to explore a range of concentrations of each
inhibitor to more accurately define the thresholds of synergy. For a
standard laboratory strain, SC5314, potent synergy was observed
such that very low concentrations of either GdA or CsA were
sufficient to abrogate MF tolerance (Figure 7). Next, we tested an
echinocandin resistant mutant that was selected in vitro in the
SC5314 background by plating on a high concentration of the
echinocandin caspofungin (CS) and contained the common Fks1
mutation F641S [12]. For this laboratory derived Fks1 mutant,
C42, synergy was observed; GdA or CsA reduced MF resistance,
though not to the same extent as for SC5314 (Figure 7). To
determine if the synergy between GdA or CsA and MF was
conserved in an isolate that evolved echinocandin resistance in a
human host, we tested a clinical isolate harboring the same F641S
Fks1 mutation (DPL15, generously provided by D. S. Perlin).
Comparable synergy between GdA and MF was observed for both
the clinical and laboratory-derived Fks1 mutants, however, the
synergy between CsA and MF was more potent against the clinical
isolate (Figure 7). Interestingly, these synergies were not observed
for all echinocandin resistant clinical isolates tested, even those
harboring the identical FKS1 mutation; of the 14 FKS1 mutants
tested, synergy was observed for 8 (data not shown). These results
suggest that Hsp90 and calcineurin enable cellular stress responses
required for clinically relevant echinocandin resistance.
Genetic compromise of HSP90 expression enhanced the
therapeutic efficacy of micafungin in a murine model of
disseminated C. albicans infection
To determine if impairing Hsp90 function holds therapeutic
potential in combination with an echinocandin, we turned to a
well-established murine model in which fungal inoculum is
delivered by tail vein injection and progresses from the
bloodstream to deep-seated infection of major organs such as
the kidney [22,40]. Due to toxicity of currently available Hsp90
inhibitors that do not distinguish pathogen from host in the
context of an acute fungal infection [22], we used genetic
regulation of HSP90 to test this hypothesis in an in vivo system.
We compared kidney fungal burden of mice infected with either a
strain with wild-type HSP90 levels or a strain with its only HSP90
allele expressed under the tetO promoter. In the absence of
tetracycline, the tetO-HSP90/hsp90D strain has HSP90 levels
comparable to a heterozygote but HSP90 expression from the
tetO promoter cannot be upregulated in response to host
temperatures or drug stress [22]. Mice infected with the tetO-
HSP90/hsp90D strain demonstrated significantly reduced kidney
fungal burden relative to those infected with a strain expressing
wild-type HSP90 levels (P,0.05, ANOVA, Bonferroni’s Multiple
Comparison Test, Figure 8). Treatment of mice with a dose of MF
that had negligible effect on mice infected with the strain with
wild-type HSP90 levels resulted in a significant reduction in fungal
Figure 6. The calcineurin-dependent transcription factor Crz1 plays a partial role in echinocandin tolerance. (A) Homozygous deletion
of CRZ1 partially reduces tolerance to MF in an MIC assay. The assay was performed and analyzed as in Figure 1A. (B) Homozygous deletion of CRZ1
partially reduces tolerance to MF on solid rich medium (YPD). Complementation with a wild-type CRZ1 allele restores tolerance. The assay was
performed and analyzed as in Figure 1B.
doi:10.1371/journal.ppat.1000532.g006
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(P,0.001, ANOVA, Bonferroni’s Multiple Comparison Test,
Figure 8). Thus, genetic compromise of HSP90 expression
enhances the efficacy of MF in a murine model.
Divergence of Hsp90 and calcineurin’s role in echinocandin
tolerance in S. cerevisiae
Given that calcineurin is the key mediator of Hsp90-dependent
resistance to azoles in both S. cerevisiae and C. albicans,w e
postulated that these key regulators of cellular signaling might also
mediate tolerance to echinocandins in both species. Consistent
with previous findings [23], we confirmed that Hsp90 and
calcineurin physically interact in S. cerevisiae (Figure 9A), as they
do in C. albicans (Figure 4). To monitor calcineurin activation in S.
cerevisiae, we used a reporter system similar to that used for C.
albicans. Cells contained an integrated plasmid with four tandem
copies of CDRE and a CYC1 minimal promoter driving lacZ [39].
As expected for an Hsp90 client protein, calcineurin activation was
blocked upon pharmacological inhibition of Hsp90 (Figure 9B,
P,0.001, ANOVA, Bonferroni’s Multiple Comparison Test). FL
activated calcineurin in S. cerevisiae (Figure 9C, P,0.0001, t-test), as
it did with C. albicans (Figure 5B), consistent with the key role for
both regulators in azole tolerance. MF also activated calcineurin in
S. cerevisiae (Figure 9C, P,0.0001) as it did in C. albicans (Figure 5A).
Despite activation of calcineurin by MF in S. cerevisiae,
compromise of calcineurin or Hsp90 function had negligible effect
on MF tolerance. Neither deletion of the gene encoding the
regulatory subunit Cnb1 nor deletion of the redundant genes
encoding the catalytic subunit Cna1 and Cna2 reduced MF
tolerance (Figure 9D). Consistent with this result, pharmacological
inhibition of calcineurin with CsA had no impact on MF
tolerance. A strain with genetically reduced Hsp90 levels (Lo90
[21]) had a modest reduction in tolerance, however, a concentra-
tion the Hsp90 inhibitor GdA that abrogates azole resistance had
Figure 7. Hsp90 and calcineurin mediate echinocandin resistance of isolates that acquired Fks1 mutations during selection in vitro
or in a human host. Pharmacological inhibition of Hsp90 or calcineurin reduces MF tolerance of a laboratory strain (SC5314), a laboratory derived
Fks1 F641S mutant (C42), and a clinical isolate harboring the same Fks1 mutation (DPL15). Checkerboards were performed in synthetic defined
medium and incubated at 30uC for 72 hours. Data was analyzed as in Figure 1A.
doi:10.1371/journal.ppat.1000532.g007
Figure 8. Genetic compromise of C. albicans HSP90 renders
micafungin (MF) more efficacious in a murine model of
disseminated disease. CD1 mice were infected with an inoculum
of 100 mlo f2 610
6 colony forming units (CFU)/ml of a strain expressing
wild-type HSP90 levels or a strain with its only HSP90 allele regulated by
tetO. MF was administered at 0.2 mg/kg intraperitoneally at one-hour
post infection and then daily, as indicated. One asterisk indicates
P,0.05; two asterisks indicate P,0.001 (ANOVA, Bonferroni’s Multiple
Comparison Test).
doi:10.1371/journal.ppat.1000532.g008
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reduction in MF tolerance of the Lo90 strain may be due to a
reduced growth rate rather than compromise of Hsp90 function.
Thus, while the functional relationship between Hsp90 and
calcineurin is conserved between C. albicans and S. cerevisiae,a si s
the activation of calcineurin in response to drug stress, these
regulators play a crucial role in cellular responses to echinocandins
in the pathogenic yeast but not in the model yeast.
Discussion
Our results establish a new role for Hsp90 in echinocandin
resistanceinthe pathogenic yeastC.albicans.Hsp90regulatescrucial
cellular responses to the cell wall stress exerted by echinocandins
such that compromising Hsp90 function reduces echinocandin
tolerance of laboratory strains and resistance of clinical isolates
(Figures 1 and 7). In a murine model of disseminated C. albicans
infection, genetic compromise of HSP90 enhances the efficacy of an
echinocandin (Figure 8). We demonstrate that calcineurin is an
Hsp90 client protein (Figure 4): calcineurin physically interacts with
Hsp90; calcineurin activation is blocked upon impairment of Hsp90
function; and calcineurin levels are depleted upon genetic reduction
of Hsp90. Our findings implicate calcineurin as the key mediator of
Hsp90-dependent echinocandin resistance. Exposure to azoles and
echinocandins activates calcineurin-dependent stress responses
(Figure 5) and the downstream effector Crz1 plays a partial role
in echinocandin tolerance (Figure 6). In addition to defining a novel
mechanism of resistance to the only new class of antifungal drugs to
Figure 9. Divergence of Hsp90 and calcineurin’s role in echinocandin tolerance in S. cerevisiae. (A) Hsp90 and calcineurin physically
interact in S. cerevisiae as measured by co-immunoprecipitation of Hsp90 (encoded by HSC82 and HSP82) with Cna1-TAP. Immunoprecipitation of
TAP-tagged Cna1 with IgG agarose co-purifies Hsp90. Hsp90 was not immunoprecipitated by IgG agarose in control cells harboring untagged Cna1.
(B) Calcineurin activation is blocked by pharmacological inhibition of Hsp90. A strain harboring a CDRE-lacZ construct was incubated in synthetic
defined medium with no treatment (U) or with 0.2 M CaCl2 (Ca) to activate calcineurin. The impact of the calcineurin inhibitor FK506 (1 mg/ml) or the
Hsp90 inhibitor GdA (5 mM) on calcineurin activation was determined by measurement of b-galactosidase activity. Data are means6standard
deviations for triplicate samples. (C) The echinocandin MF and the azole FL activate calcineurin. A strain harboring a CDRE-lacZ construct was
incubated in synthetic defined medium without treatment (U), with 30 ng/ml MF for 8 hours, or with 16 mg/ml FL for 24 hours. Data are
means6standard deviations for triplicate samples. (D) Compromising calcineurin or Hsp90 has minimal effect on tolerance to MF in S. cerevisiae in an
MIC assay. The effects of CsA are not due to inhibition of calcineurin given that genetic compromise of calcineurin by deletion of the regulatory
subunit encoded by CNB1 or by deletion of the catalytic subunit encoded by CNA1 and CNA2 has no impact on MF tolerance. The assay was
performed in synthetic defined medium at 25uC and was analyzed as in Figure 1A.
doi:10.1371/journal.ppat.1000532.g009
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characterization of an Hsp90 client protein in C. albicans.
The requirement for Hsp90 and calcineurin in mediating
crucial cellular responses to the echinocandins in C. albicans but not
in S. cerevisiae (Figures 1, 2, and 9) stands in contrast to the
conserved role for both regulators in cellular responses to azoles in
both species. It is intriguing that calcineurin is activated in
response to echinocandin stress in S. cerevisiae yet the functional
consequence of deleting calcineurin is negligible for this trait
(Figure 9). Activation of signaling molecules does not always
predict functional consequences of their deletion under equivalent
conditions. For example, Mkc1, the mitogen activated protein
kinase (MAPK) in the PKC pathway, is activated by hydrogen
peroxide but is not required for survival under this condition [43].
Our results suggest that there may be other redundant pathways
operating in parallel with Hsp90 and calcineurin in S. cerevisiae.
The protein kinase C (PKC) cell wall integrity pathway has a well-
established function in mediating tolerance to echinocandins in S.
cerevisiae [44,45]. In C. albicans, the PKC pathway is activated
under diverse stress conditions [43] and works in concert with
calcineurin and the high osmolarity glycerol pathway to regulate
chitin synthesis, which can enhance tolerance to echinocandins
[15,16]. There may be considerable interaction between PKC
signaling, calcineurin, and Hsp90. In S. cerevisiae, expression of one
of the two partially redundant genes encoding the essential (1,3)-b-
D-glucan synthase activity, FKS2, is regulated by both PKC
signaling and calcineurin [46,47]. In S. cerevisiae, Hsp90 may also
interact with PKC signaling by chaperoning PKC [48] and the
MAPK Slt2 [49,50].
Stress response signaling and canonical resistance mechanisms
are intimately connected in defining a resistance phenotype.
Compromising Hsp90 or calcineurin blocks the stress responses
crucial for basal tolerance of strains that were not previously
exposed to echinocandins (Figures 1, 2, and 3). There is
heterogeneity in the phenotypic consequences of compromising
these cellular regulators in strains that acquired resistance by
mutation in the drug target Fks1 (Figure 7). For some isolates,
resistance is not affected (data not shown), while for others
resistance is reduced, though not to the extent of a sensitive strain
(Figure 7). This suggests that Hsp90 is not required to enable the
phenotypic consequences of the mutant Fks1 protein. Rather, in
many of the Fks1 mutants, Hsp90 and calcineurin-dependent
stress responses contribute to the overall resistance phenotypes.
Notably, the calcineurin inhibitor was more effective than the
Hsp90 inhibitor at reducing MF resistance of some clinical isolates
(Figure 7 and data not shown); this may be due to additional effects
of CsA on targets distinct from calcineurin. The accumulation of
mutations that reduce the dependence of resistance on Hsp90 is
reminiscent of the evolution of azole resistance from Hsp90-
dependence towards Hsp90-independence observed in isolates
that evolved azole resistance in a human host [21].
Hsp90 chaperones many cellular regulators in addition to
calcineurin. High-throughput genomic and proteomic studies
suggest that Hsp90 may interact with up to 10% of the S. cerevisiae
proteome [24]. Thus, Hsp90 is poised to regulate responses to
antifungal drugs via other signal transduction pathways governing
cellular stress responses. That Hsp90 regulates cellular responses to
antifungal drugs targeting both the cell membrane and the cell
wall via calcineurin emphasizes the importance of calcineurin as
regulator of cellular stress responses. Cases of discordance between
the phenotypic effects of compromising Hsp90 versus compro-
mising calcineurin may reflect the relative importance of other
Hsp90 client proteins in a particular trait or may reflect specificity
of the agents used to inhibit these regulators [51].
Our results suggest that targeting Hsp90 may provide a
powerful therapeutic strategy in the treatment of fungal infectious
disease. In vitro, compromising Hsp90 function enhances the
efficacy of echinocandins against isolates that evolved resistance in
a human host and against isolates not previously exposed to
echinocandins (Figure 1, 3, and 7). In a murine model of
disseminated candidiasis, genetic impairment of HSP90 expression
enhances the efficacy of an echinocandin (Figure 8). These findings
add a new dimension to combinatorial therapeutic strategies for
the treatment of C. albicans infections. Our previous work
established that genetic reduction of Hsp90 levels enhances the
efficacy of fluconazole in a murine model of disseminated C.
albicans infection [22] and that further genetic depletion of C.
albicans Hsp90 results in complete clearance of an infection in the
murine model [40]. These studies establish firm proof-of-principle
of Hsp90 as a therapeutic target. Current Hsp90 inhibitors that
are well-tolerated in humans as anti-cancer agents exhibit toxicity
in the mouse model in the context of an acute fungal infection
[22]. However, in an invertebrate model of fungal pathogenesis,
these pharmacological inhibitors of Hsp90 function enhance the
efficacy of the two most widely deployed classes of antifungal
drugs, azoles and echinocandins, against the two leading fungal
pathogens of humans, Candida albicans and Aspergillus fumigatus [22].
Thus, compromising Hsp90 has broad therapeutic potential in
combinatorial therapeutic regimens against fungal infections.
Further support for targeting Hsp90 in antifungal therapy
emerges from a recombinant antibody against the C. albicans
chaperone.This recombinantantibodyhadtherapeuticbenefitsina
clinical trial in combination with amphotericin B, which targets
ergosterol [52]. This antibody also demonstrated synergy with the
echinocandin caspofungin in a murine model [53]. The mechanism
by which this antibody works, however, is unclear as the antibody is
unlikely to be able to cross the fungal cell wall and access the cytosol
of intact fungal cells, where Hsp90 regulates calcineurin-dependent
signaling governing drug resistance. The antibody may work by
influencing host immune responsesto the pathogen.Consistentwith
this thinking,heat-shock proteinsareimmunodominantantigens for
the recognition of many pathogens and play a central role in
mediating both innate and adaptive immune responses [54,55].
Hsp90 has taken center stage as a therapeutic target for diverse
diseases including cancer and neurodegeneration. Our findings
suggest that Hsp90 may provide a much-needed target for life-
threatening fungal infectious disease. Inhibitors of Hsp90 and
calcineurin both have potent anti-malarial activity, thus extending
their impact to the protozoan parasite Plasmodium falciparum [56].
Compromising host Hsp90 function in the context of an acute fungal
infection is not well tolerated [22]. Perhaps in a related manner, the
utility of calcineurin inhibitors in antifungal therapy has been
complicated by their immunosuppressive effects [57]. Thus, the
challenge in successfully exploiting this strategy lies in developing
fungal selective inhibitors of Hsp90 or in targeting fungal specific
components of the Hsp90 chaperone machine. Our findings may
point to broader paradigm of targeting fungal stress response
pathwaysinthetreatmentoflife-threateningfungalinfectiousdisease.
Materials and Methods
Strains and Culture Conditions
Archives of C. albicans and S. cerevisiae strains were maintained in
at 280uC in 25% glycerol. Strains were grown in either YPD (1%
yeast extract, 2% bactopeptone, 2% glucose), YPM (as YPD
except with 2% maltose), or in synthetic defined media (yeast
nitrogen base, 2% glucose) and supplemented with the required
amino acids. 2% agar was added for solid media. Strains were
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study are listed in Table S1. Strain construction is described in
Text S1.
Plasmid Construction
Recombinant DNA procedures were performed according to
standard protocols. Plasmids used in this study are listed in Table
S2. Plasmid construction is described in the Text S1. Plasmids
were sequenced to verify the absence of any nonsense mutations.
Primers used in this study are listed in Table S3.
Minimum Inhibitory Concentration and Checkerboard
Assays
Antifungal susceptibility was determined in flat bottom, 96-well
microtiter plates (Sarstedt) using a modified broth microdilution
protocol, as described [21]. Minimum inhibitory concentration
(MIC) tests were set up in a total volume of 0.2 ml/well with 2-fold
dilutions of micafungin (MF, generously provided by Julia R.
Ko ¨hler) or caspofungin (CS, generously provided by Rochelle
Bagatell). Echinocandin gradients were typically from 2 mg/ml
down to 0 with the following concentration steps in mg/ml: 1, 0.5,
0.25, 0.125, 0.0625, 0.03125, 0.015625, 0.0078125, 0.00390625,
0.00195313. For gradients from 16 mg/ml down to 0, the
concentration steps in mg/ml were: 8, 4, 2, 1, 0.5, 0.25, 0.125,
0.0625, 0.03125, 0.015625. Cell densities of overnight cultures
were determined and dilutions were prepared such that ,10
3 cells
were inoculated into each well. Geldanamycin (GdA, A.G.
Scientific, Inc.) and radicicol (RAD, A.G. Scientific, Inc.) were
used to inhibit Hsp90 at the indicated concentrations, and
cyclosporin A (CsA, CalBiochem) and FK506 (A.G. Scientific,
Inc.) were used to inhibit calcineurin at the indicated concentra-
tions. Checkerboard assays were set up in a total volume of
0.2 ml/well with 2-fold dilutions of MF across the x-axis of the
plate and 2-fold dilutions of either GdA or CsA across the y-axis of
the plate. Plates were inoculated as with MIC tests. Dimethyl
sulfoxide (DMSO, Sigma Aldrich Co.) was the vehicle for GdA,
RAD, CsA, and FK506. Sterile water was the vehicle for MF and
CS. Plates were incubated in the dark at 30uC for the time period
indicated, at which point plates were sealed and re-suspended by
agitation. Absorbance was determined at 600 nm using a
spectrophotometer (Molecular Devices) and was corrected for
background from the corresponding medium. Each strain was
tested in duplicate on at least two occasions. MIC data was
quantitatively displayed with color using the program Java
TreeView 1.1.3 (http://jtreeview.sourceforge.net).
Spotting Assays
Strains were grown overnight to saturation in YPD and cell
concentrations were standardized based on optical density. Five-
fold dilutions (from ,1610
6 cells/ml) were spotted onto indicated
media using a spotter (Frogger, V&P Scientific, Inc). Plates were
photographed after 2 days in the dark at 30uC. All spottings were
done in duplicate on at least two separate occasions.
b-Galactosidase Assays
C. albicans cultures were grown overnight in YPD at 30uC with
or without 10 mM CsA, 5 mg/ml FK506, 5 mM GdA, or 5 mM
RAD. Cells were diluted to OD600 of 0.5 and grown at 25uC for
2 h, at which point they were treated with MF, FL, or CaCl2,a s
indicated. S. cerevisiae cultures were grown overnight in synthetic
defined medium containing ammonium chloride at 30uC with
1 mg/mL FK506 or 5 mM GdA, as indicated. Cells were diluted to
OD600 of 0.3 and treated with 0.2 M CaCl2, FK506, or GdA, as
indicated. Cells were grown for 3 hours at 25uC. Protein was
extracted as described [46,58], and protein concentrations were
determined by Bradford analysis. b-galactosidase activity was
measured using the substrate ONPG (O-nitrophenyl-b-D-galacto-
pyranosidase, Sigma Aldrich Co.), as described [46]. b-galactosi-
dase activity is given in units of nanomoles ONPG converted per
minute per milligram of protein (Miller Units). Statistical
significance was evaluated using GraphPad Prism 4.0.
Immunoprecipitation
Yeast cultures were grown overnight in YPD at 30uC. Cells
were diluted to OD600 of 0.2 in 40 ml and grown to mid-log phase.
Cells were washed with sterile H20 and resuspended in 500 mlo f
lysis buffer containing 20 mM Tris pH 7.5, 100 mM KCl, 5 mM
MgCl and 20% glycerol, with one protease inhibitor cocktail
(complete, EDTA-free tablet, Roche Diagnostics) per 10 ml,
1 mM PMSF (EMD Chemicals) and 20 mM sodium molybdate
(Sigma Aldrich Co.) added fresh before use. Cells were transferred
to a 2 mL screw-cap tube and the tube was filled, alternating with
glass beads and additional lysis buffer until the beads were just
below the meniscus at the top of the tube to reduce foaming during
bead beating. Cells were disrupted by bead beating twice for
4 minutes with a 10 minute break on ice between cycles. Lysates
were recovered by piercing a hole in the bottom of each tube,
placing each tube in a larger 14 ml tube, and centrifuging at
13086g for three 5-minute cycles, recovering the lysates at each
interval. Total collected lysates were cleared by centrifugation at
208176g for 10 minutes at 4uC and protein concentrations were
determined by Bradford analysis.
Anti-FLAG immunoprecipitations were done by diluting
protein samples to 1 mg/ml in tris-buffered saline with 20 mM
sodium molybdate and incubating with anti-FLAG M2 affinity
agarose (Sigma Aldrich Co.) that was washed twice with tris-
buffered saline prior to use, as per the manufacturer’s specifica-
tions, at 4uC overnight. Unbound material was removed by three
washes with 1 ml tris-buffered saline and protein was eluted by
boiling the sample in one volume of 26sample buffer.
Anti-IgG immunoprecipitations were done by diluting protein
samples to 1 mg/ml in lysis buffer with 0.2% tween and
incubating with rabbit IgG agarose (Sigma Aldrich Co.) that was
washed three times with lysis buffer prior to use, at 4uC overnight.
Unbound material was removed by washing six times with 1 ml
lysis buffer with 0.1% tween and protein was eluted by boiling the
sample in one volume of 26sample buffer.
Immune Blot Analysis
Yeast cultures were grown to mid-log phase, protein was
extracted as above, and protein concentrations were determined
by Bradford analysis. Protein samples were mixed with one-fifth
volume of 66sample buffer, were boiled for 5 minutes, and then
separated on a 10% SDS-PAGE gel. Protein was electrotrans-
ferred to PVDF membrane (Bio-Rad Laboratories, Inc.) and
blocked with 5% skim milk in phosphate buffered saline with 0.1%
tween. Blots were hybridized with antibody against CaHsp90
(1:10000 dilution, [59]), histone H3 (1:3000 dilution; Abcam
ab1791), FLAG (1:10000, Sigma Aldrich Co.), Hsc82/Hsp82
(1:5000, [60]), or TAP (1:5000, Open Biosystems).
Murine Model of C. albicans Infection
Inoculum was prepared as described for injection of 100 mLo fa
2610
6 CFU/mL suspension [22]. Inoculum concentrations were
verified by cell counts and CFU measurements. Male CD1 mice
(Charles River Laboratories) age 8 weeks (weight 30–34 g) were
infected via the tail vein. For infection with the wild type, the
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mice for the MF treatment group. For the tetO-HSP90/hsp90D
strain the sample sizes were n=7 mice for the untreated group and
n=8 for the MF treatment group. An initial dose finding
experiment was performed to determine a concentration of MF
that would have negligible effect on fungal burden of mice infected
with the wild type; a dose of 2 mg/kg MF (Astellas Pharma, Inc;
Deerfield, IL) delivered intraperitoneally at one-hour post
infection and then daily resulted in clearance of the fungal burden
(data not shown), while a dose of 0.2 mg/kg had no significant
effect and was chosen as the dose for this study. Mice were
observed three times daily for signs of illness and weighed daily. At
day 4 following injection, mice were sacrificed by CO2
asphyxiation and the left kidney was removed aseptically,
homogenized in PBS and serial dilutions plated for determination
of kidney fungal burden, as described [22]. CFU values were
expressed as CFU/g of tissue, log-transformed and compared
using an ANOVA with post-hoc testing of significance between
groups (GraphPad Prism 4.0). Murine work was performed under
a protocol approved by the Institutional Animal Use and Care
Committee at Duke University Medical Center.
Supporting Information
Text S1 Supplemental Materials and Methods
Found at: doi:10.1371/journal.ppat.1000532.s001 (0.06 MB
DOC)
Figure S1 Hsp90 plays a crucial role in echinocandin tolerance
of Candida albicans. (A) Pharmacological inhibition of Hsp90 with
geldanamycin (GdA) or radicicol (RAD) reduces micafungin (MF)
tolerance of C. albicans laboratory strains in an MIC assay. Assays
were done in rich medium (YPD) at 30uC for 72 hours. Optical
densities were averaged for duplicate measurements and normal-
ized relative to MF-free controls (see colour bar). (B) Pharmaco-
logical inhibition of Hsp90 with GdA or inhibition of calcineurin
with cyclosporine A (CsA) reduces caspofungin (CS) tolerance of C.
albicans laboratory strains in an MIC assay. Assays were done in
rich medium (YPD) at 30uC for 72 hours. Data was analyzed as in
part A. (C) Pharmacological inhibition of Hsp90 with GdA or
pharmacological inhibition of calcineurin with CsA reduces CS
tolerance of C. albicans laboratory strains in an MIC assay. Assays
were done in RPMI at 30uC for 72 hours. Data was analyzed as in
part A. (D) C. albicans laboratory strains are susceptible to CS in an
E-test. Resistance of standard C. albicans laboratory strains to CS is
shown on RPMI solid medium. CS test strips (Etest, AB Biodisk)
produced a gradient of drug concentration, highest at the top.
Plates were incubated at 30uC for 48 hours.
Found at: doi:10.1371/journal.ppat.1000532.s002 (0.73 MB TIF)
Figure S2 Tagged alleles of Candida albicans CNA1 and HSP90
are functional. (A) The Candida albicans HIS-FLAG tagged allele of
CNA1 is functional. Cells were spotted in five-fold dilutions (from
1610
6 cells/ml) onto solid rich medium with or without CaCl2 to
assess calcineurin function. The mutant lacking the regulatory
subunit of calcineurin required for its activation, Cnb1, is
hypersensitive to calcium stress. The strain with its only allele
encoding the catalytic subunit of calcineurin C-terminally HIS-
FLAG tagged shows no increase in sensitivity to calcium stress,
consistent with functionality of the tagged allele. Plates were
photographed after 48 hours in the dark at 30uC. (B) The Candida
albicans TAP-tagged allele of HSP90 is functional. Cells were
spotted as in part A onto solid rich medium to assess function of
Hsp90-TAP. Since Hsp90 is essential, the equivalent growth of the
strain with its only HSP90 allele TAP tagged compared to the
untagged counterpart indicates functionality of the tagged allele.
Plates were photographed after 48 hours in the dark at 30uC.
Found at: doi:10.1371/journal.ppat.1000532.s003 (1.68 MB TIF)
Table S1 Strains used in this study.
Found at: doi:10.1371/journal.ppat.1000532.s004 (0.08 MB
DOC)
Table S2 Plasmids used in this study.
Found at: doi:10.1371/journal.ppat.1000532.s005 (0.03 MB
DOC)
Table S3 Primers used in this study.
Found at: doi:10.1371/journal.ppat.1000532.s006 (0.03 MB
DOC)
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